366-47-2 Usage
Description
(3-Fluoro-benzoylamino)-acetic acid is a chemical compound with the molecular formula C9H8FNO3. It is a derivative of benzoic acid and contains a fluorine atom. (3-FLUORO-BENZOYLAMINO)-ACETIC ACID is known for its potential use as a pharmaceutical intermediate in the synthesis of various drugs, as well as its applications in organic synthesis and research purposes. As an acetic acid derivative, it holds promise for applications in the fields of medicine and biochemistry. Its unique properties and potential uses make (3-Fluoro-benzoylamino)-acetic acid an important chemical compound for further study and exploration in various scientific and industrial applications.
Uses
Used in Pharmaceutical Industry:
(3-Fluoro-benzoylamino)-acetic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and properties make it a valuable component in the development of new medications, potentially leading to the creation of innovative treatments for a range of medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, (3-Fluoro-benzoylamino)-acetic acid serves as a key building block for the creation of more complex organic compounds. Its presence in these reactions can lead to the formation of new molecules with unique properties and potential applications in various industries.
Used in Research and Development:
(3-Fluoro-benzoylamino)-acetic acid is utilized in research and development settings to explore its properties and potential applications further. Scientists and researchers can use this compound to investigate its interactions with other chemicals, its effects on biological systems, and its potential uses in various fields, such as medicine and biochemistry.
Used in Medicine and Biochemistry:
As an acetic acid derivative, (3-Fluoro-benzoylamino)-acetic acid may have applications in medicine and biochemistry. Its unique structure and properties could potentially contribute to the development of new diagnostic tools, therapeutic agents, or other medical advancements. Further research and exploration are necessary to fully understand and harness its potential in these fields.
Check Digit Verification of cas no
The CAS Registry Mumber 366-47-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,6 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 366-47:
(5*3)+(4*6)+(3*6)+(2*4)+(1*7)=72
72 % 10 = 2
So 366-47-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H8FNO3/c10-7-3-1-2-6(4-7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)/p-1
366-47-2Relevant articles and documents
Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents
Gu, Xiaoke,Zhang, Yinpeng,Zou, Yueting,Li, Xin,Guan, Mingyu,Zhou, Qingqing,Qiu, Jingying
, (2020/12/09)
As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.
Synthesis of di- and tri-substituted imidazole-4-carboxylates via PBu3-mediated [3+2] cycloaddition
Hsu, Mei-Yuan,Dietrich, Justin,Hulme, Christopher,Shaw, Arthur Y.
, p. 1538 - 1542 (2013/05/21)
Some new di- and trisubstituted imidazole-4-carboxylates were prepared from amidoacetic acids 3 in the present report. The key step to establish such imidazole- 4-carboxylates stemmed from the PBu3-mediated [3+2] cycloaddition between in situ-generated Δ2-oxazolinone 4 and ethyl cyanoformate6. Our results indicated that trisubstituted imidazoles 7-20 were afforded in better yields than those of disubstituted imidazoles 21-27. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications1 to view the free supplemental file. Copyright Taylor & Francis Group, LLC.
